Phase 2 Trial of Daridorexant for PTSD Under Adaptive Platform Design
A Phase 2 trial is underway to evaluate daridorexant's safety and efficacy in PTSD patients.
Company
Pharmaceutical intelligence for Idorsia Pharmaceuticals with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.